ATE429423T1 - Neue zwischenprodukte für linezolid und verwandte verbindungen - Google Patents

Neue zwischenprodukte für linezolid und verwandte verbindungen

Info

Publication number
ATE429423T1
ATE429423T1 AT04770673T AT04770673T ATE429423T1 AT E429423 T1 ATE429423 T1 AT E429423T1 AT 04770673 T AT04770673 T AT 04770673T AT 04770673 T AT04770673 T AT 04770673T AT E429423 T1 ATE429423 T1 AT E429423T1
Authority
AT
Austria
Prior art keywords
fluoro
linezolid
morpholinyl
related compounds
intermediate products
Prior art date
Application number
AT04770673T
Other languages
English (en)
Inventor
Rao Dodda Mohan
Reddy Pingili Krishna
Original Assignee
Symed Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35784913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE429423(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symed Labs Ltd filed Critical Symed Labs Ltd
Application granted granted Critical
Publication of ATE429423T1 publication Critical patent/ATE429423T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT04770673T 2004-07-20 2004-07-20 Neue zwischenprodukte für linezolid und verwandte verbindungen ATE429423T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000218 WO2006008754A1 (en) 2004-07-20 2004-07-20 Novel intermediates for linezolid and related compounds

Publications (1)

Publication Number Publication Date
ATE429423T1 true ATE429423T1 (de) 2009-05-15

Family

ID=35784913

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04770673T ATE429423T1 (de) 2004-07-20 2004-07-20 Neue zwischenprodukte für linezolid und verwandte verbindungen

Country Status (7)

Country Link
US (1) US7429661B2 (de)
EP (1) EP1768967B1 (de)
AT (1) ATE429423T1 (de)
DE (1) DE602004020812D1 (de)
ES (1) ES2325401T3 (de)
PL (1) PL1768967T3 (de)
WO (1) WO2006008754A1 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100884A1 (de) 2003-10-16 2009-09-16 Symed Labs Limited Kristalline Form von Linezolid
WO2005099353A2 (en) * 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
CN102442970A (zh) 2006-05-31 2012-05-09 雅培制药有限公司 用作大麻素受体配位体的噻唑化合物及其用途
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
ES2645995T3 (es) 2006-05-31 2017-12-11 Abbvie Inc. Compuestos como ligandos del receptor cannabinoide y sus usos
WO2008121558A1 (en) 2007-03-28 2008-10-09 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2160393A1 (de) 2007-05-18 2010-03-10 Abbott Laboratories Neue verbindungen als cannabinoidrezeptorliganden
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2274306A1 (de) 2008-03-11 2011-01-19 Abbott Laboratories Neue verbindungen als cannabinoidrezeptorliganden
ES2397764T3 (es) 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia
CA2731102A1 (en) 2008-08-15 2010-02-18 Abbott Laboratories Imine derivatives as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
TW201016692A (en) 2008-09-16 2010-05-01 Abbott Lab Novel compounds as cannabinoid receptor ligands
EP2352727A1 (de) 2008-10-17 2011-08-10 Abbott Laboratories Trpv1-antagonisten
JP2012505907A (ja) 2008-10-17 2012-03-08 アボット・ラボラトリーズ Ｔｒｐｖ１拮抗薬
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MX363470B (es) 2008-12-05 2019-03-25 Abbvie Inc Derivados de sulfonamida como agentes inductores de apoptosis selectiva de bcl-2 para el tratamiento del cancer y enfermedades inmunes.
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
CN101774978B (zh) * 2009-01-13 2011-09-21 联化科技股份有限公司 一种利奈唑胺的制备方法及其中间体
BRPI1006115A8 (pt) 2009-01-19 2017-09-26 Abbott Lab "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
CA2747835A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
ES2542234T3 (es) 2009-03-27 2015-08-03 Abbvie Inc. Compuestos como ligandos de receptores cannabinoides
WO2010111572A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2411370B1 (de) 2009-03-27 2015-04-22 AbbVie Inc. Verbindungen als cannabinoidrezeptorliganden
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2759182C (en) 2009-05-26 2016-06-07 Abbott Laboratories (hetero)aryl substituted sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-oxy) benzamide compounds and their use as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138828A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Potassium channel modulators
WO2011053740A1 (en) 2009-10-28 2011-05-05 Belkin International, Inc. Portable multi-media communication device protective carrier and method of manufacture therefor
CA2778266A1 (en) 2009-11-25 2011-06-03 Abbott Laboratories Potassium channel modulators
TW201130855A (en) 2009-12-16 2011-09-16 Abbott Lab Prodrug compounds useful as cannabinoid ligands
WO2011077310A1 (en) 2009-12-26 2011-06-30 Alembic Limited Process for the preparation of linezolid
BR112012024382A2 (pt) 2010-03-25 2017-08-08 Abbvie Inc agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunesças
JP5865898B2 (ja) 2010-04-30 2016-02-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ リネゾリドを調製するためのプロセス
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
WO2011159785A1 (en) 2010-06-15 2011-12-22 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
CN102311400A (zh) * 2010-06-29 2012-01-11 翔真生物科技股份有限公司 制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法
RU2013110324A (ru) 2010-08-10 2014-09-20 Эббви Инк. Новые модуляторы trpv3
EP2603506A1 (de) 2010-08-11 2013-06-19 Synthon BV Verfahren zur herstellung von linezolid
CN103140487A (zh) 2010-08-11 2013-06-05 斯索恩有限公司 制备利奈唑胺的方法
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2810478A1 (en) 2010-09-07 2012-03-15 Symed Labs Limited Processes for the preparation of 4-{4-[5(s)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one
CA2810954A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
MX349533B (es) 2010-10-29 2017-08-02 Abbvie Inc Dispersiones solidas que contienen un agente inductor de apoptosis.
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
MX2013005479A (es) 2010-11-15 2013-06-12 Abbvie Inc Inhibidores de nampt.
UY33726A (es) 2010-11-15 2012-06-29 Abbott Lab Inhibidores de nampt y rock
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
US8609674B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
BR112013012740A2 (pt) 2010-11-23 2016-09-13 Abbvie Inc sais e formas cristalinas de um agente que induz apoptose
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
HRP20151315T1 (hr) 2011-02-24 2016-01-01 Lee Pharma Limited Novi postupak za proizvodnju linezolida i njegovih novih međuprodukata
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
CA2831146C (en) 2011-03-25 2019-06-04 Abbvie Inc. Trpv1 antagonists
US9221771B2 (en) 2011-04-11 2015-12-29 Sandoz Ag Method for the preparation of substituted oxazolidinones
CN102229577A (zh) * 2011-05-11 2011-11-02 石药集团中诺药业（石家庄）有限公司 利奈唑胺中间体的制备及纯化方法
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012158399A1 (en) 2011-05-13 2012-11-22 Abbott Laboratories Condensed 2 - carbamoylpyridazinones as potassium channel modulators
CN102304125B (zh) * 2011-07-05 2014-02-19 浙江亚太药业股份有限公司 一种用于制备利奈唑胺的中间体
EP2739614B1 (de) 2011-08-05 2017-02-22 AbbVie Deutschland GmbH & Co KG Aminochromanderivate, pharmazeutische zusammensetzungen davon und ihre therapeutische verwendung
US20140378682A1 (en) 2011-09-08 2014-12-25 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
TWI571466B (zh) 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
TWI561521B (en) 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2014530911A (ja) 2011-10-24 2014-11-20 アッヴィ・インコーポレイテッド Ｔｒｐｖ３モジュレーターとしてのメタノール誘導体
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CN103103229B (zh) * 2011-11-15 2015-03-18 安琪酵母股份有限公司 一种利奈唑酮中间体的合成方法
CA2853254A1 (en) 2011-11-18 2013-05-23 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
HK1206744A1 (en) 2012-04-20 2016-01-15 Abbvie Inc. Isoindolone derivatives
MX2014013758A (es) 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
CN104583194A (zh) 2012-05-11 2015-04-29 艾伯维公司 作为nampt抑制剂的哒嗪和吡啶衍生物
AR091022A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
MX2014013752A (es) 2012-05-11 2014-12-08 Abbvie Inc Inhibidores de nampt.
US20130317054A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317055A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
CN103420933B (zh) * 2012-05-26 2016-03-02 鲁南制药集团股份有限公司 一种利奈唑胺的制备方法
RU2632915C2 (ru) 2012-06-12 2017-10-11 Эббви Инк. Производные пиридинона и пиридазинона
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103570639B (zh) * 2012-08-08 2016-02-03 成都国弘医药有限公司 一种利奈唑胺的合成方法
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
UY35029A (es) 2012-09-14 2014-04-30 Abbvie Inc Derivados tricíclicos de quinolinas y de quinoxalinas
CN102887871B (zh) * 2012-09-26 2015-12-02 苏州敬业医药化工有限公司 3-取代苯基-5-氨甲基噁唑烷-2-酮的制备方法
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid
CA2901929A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
BR112015021549A2 (pt) 2013-03-13 2017-07-18 Abbvie Inc inibidores de piridina cinase cdk9
JP2016512560A (ja) 2013-03-14 2016-04-28 アッヴィ・インコーポレイテッド ピロロピリミジン系ｃｄｋ９キナーゼ阻害薬
TW201444836A (zh) 2013-03-14 2014-12-01 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2970258B1 (de) 2013-03-14 2018-04-18 AbbVie Deutschland GmbH & Co KG Neuartige inhibitorverbindungen der phosphodiesterase typ 10a
AU2014234077A1 (en) 2013-03-14 2015-10-01 Abbvie Inc. Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
US9593104B2 (en) 2013-03-14 2017-03-14 Benova Labs Pvt. Limited Process for the preparation of oxazolidinone derivatives
WO2014140186A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586913B2 (en) 2013-04-25 2017-03-07 Symed Labs Limited Processes for the preparation of linezolid using novel intermediates
CN105992764A (zh) 2013-10-17 2016-10-05 艾伯维德国有限责任两合公司 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途
KR20160062165A (ko) 2013-10-17 2016-06-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 아미노테트랄린 및 아미노인단 유도체, 이들을 포함하는 약제학적 조성물, 및 치료에서 이들의 용도
US9840495B2 (en) 2013-12-20 2017-12-12 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
US9328112B2 (en) 2014-02-06 2016-05-03 Abbvie Inc. Tetracyclic CDK9 kinase inhibitors
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
CN105315231A (zh) * 2014-06-11 2016-02-10 成都自豪药业有限公司 利奈唑胺相关物质的制备方法
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20180243298A1 (en) 2015-04-02 2018-08-30 Abbvie Inc. Trpv3 modulators
EP3636651A1 (de) 2015-11-25 2020-04-15 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- oder pyrido-oxazepine, die ein sauerstoff enthaltende substituent tragen, und ihre verwendung zur behandlung von 5ht2c abhängige krankheiten
CN105566242B (zh) * 2016-01-12 2017-12-05 江苏豪森药业集团有限公司 利奈唑胺及其中间体的制备方法
US9643939B1 (en) 2016-04-18 2017-05-09 Optimus Drugs Private Limited Process for the preparation of linezolid
EP3250568A4 (de) * 2016-04-21 2018-08-01 Optimus Drugs Pvt Ltd Verbessertes verfahren zur herstellung von linezolid
USRE47606E1 (en) 2016-04-21 2019-09-17 Optimus Drugs Private Limited Process for the preparation of linezolid
WO2017193872A1 (en) 2016-05-07 2017-11-16 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2018095432A1 (en) 2016-11-28 2018-05-31 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
US20200039930A1 (en) 2017-03-21 2020-02-06 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
KR102630069B1 (ko) 2017-04-18 2024-01-26 포천 파마슈티컬즈, 엘티디. 아폽토시스-유도제
BR112020018444A2 (pt) 2018-03-14 2020-12-29 Fochon Pharmaceuticals, Ltd. Compostos de (2-azabiciclo[3,1,0]hexan-2-il)pirazolo[1,5-a]pirimidina substituída e imidazo[1,2-b]piridazina como inibidores de trk cinases
EP3768661B1 (de) 2018-03-23 2024-05-01 Fochon Pharmaceuticals, Ltd. Deuterierte verbindungen als rock-inhibitoren
CN109232457A (zh) * 2018-03-26 2019-01-18 华夏生生药业(北京)有限公司 一种利奈唑胺的制备方法
CN108892663A (zh) * 2018-08-10 2018-11-27 泰州申合泰尔生物医药有限公司 一种合成利伐沙班的中间体、合成方法和用途
WO2021184339A1 (en) 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
CN113045509B (zh) * 2021-06-01 2021-10-22 上海翰森生物医药科技有限公司 利奈唑胺的工业生产方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2810349A1 (de) * 1978-03-10 1979-09-20 Kali Chemie Pharma Gmbh Verfahren zur herstellung von 3-hydroxy-6-phenyl-1,2,3,4-tetrahydro- 1,5-benzodiazocinen
FR2506769A2 (fr) * 1978-06-09 1982-12-03 Delalande Sa Para-((cyano-5 n pentyl-1) phenyl)-3 methoxymethyl-5 oxazolidinone-2, son procede de preparation et ses applications en therapeutique
US4340606A (en) * 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2608604B1 (fr) 1986-12-19 1989-04-28 Delalande Sa Derives 5-hydroxyethyles de l'oxazolidinone-2, leurs procedes de preparation et leurs applications en therapeutique
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1114819B1 (de) 1996-04-11 2008-01-09 Pharmacia & Upjohn Company LLC Verfahren zur Herstellung von Oxazolidinonen
WO1999024393A1 (en) 1997-11-07 1999-05-20 Pharmacia & Upjohn Company Process to produce oxazolidinones
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CN1155585C (zh) 2001-12-19 2004-06-30 中国医学科学院医药生物技术研究所 3,5－取代噁唑烷酮衍生物及其制备方法和应用
WO2005099353A2 (en) * 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds

Also Published As

Publication number Publication date
US7429661B2 (en) 2008-09-30
US20060247435A1 (en) 2006-11-02
ES2325401T3 (es) 2009-09-03
DE602004020812D1 (de) 2009-06-04
PL1768967T3 (pl) 2009-09-30
EP1768967A1 (de) 2007-04-04
WO2006008754A1 (en) 2006-01-26
EP1768967B1 (de) 2009-04-22

Similar Documents

Publication Publication Date Title
ATE429423T1 (de) Neue zwischenprodukte für linezolid und verwandte verbindungen
WO2005099353A3 (en) A novel process for the preparation of linezolid and related compounds
Cole Recent stereoselective synthetic approaches to β-amino acids
Hirabayashi et al. Highly stereoselective synthesis of homoallylic amines based on addition of allyltrichlorosilanes to benzoylhydrazones
AU2010242496B2 (en) Processes for the preparation of Rivaroxaban and intermediates thereof
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
CA2434937A1 (en) Phenyl derivatives
ATE455119T1 (de) Thiazolo-, oxazalo und imidazolo- chinazolinverbindungen, die dazu fähig sind, proteinkinasen zu hemmen
CZ20031799A3 (cs) Nové heterocyklické sloučeniny s antibakteriálním účinkem, způsob jejich výroby a farmaceutické kompozice s jejich obsahem
SI2824100T1 (en) 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase
AR038915A1 (es) Derivados de aminoindazoles, procedimiento de preparacion e intermedios de este procedimiento, medicamentos y composiciones farmaceuticas que contienen al compuesto
JP2006522037A5 (de)
EA201391647A1 (ru) Способ получения ривароксабана и промежуточные соединения, получаемые в указанном способе
WO2016030310A1 (en) Substituted azetidine derivatives as taar ligands
Carroccia et al. Straightforward access to 4-membered sulfurated heterocycles: introducing a strategy for the single and double functionalization of thietane 1-oxide
CA2449578A1 (en) Pyrrolidine oxadiazole- and thiadiazole derivatives
GEP20063896B (en) New heterocyclic oxime compound, method for production of the same and pharmaceutical composition comprising the same
Gugelchuk et al. Stereoselective organometallic reactions: a force field study of. pi.-allyl intermediates in nickel (0)-catalyzed cycloadditions
ATE543805T1 (de) Verfahren zur herstellung von oxazolidinonderivaten
KR20070027614A (ko) 항박테리아제로서의3-[4-(6-｛4,5-디히드로이속사졸-3-일｝피리딘-3-일)-3-페닐]-5-(1ｈ-1,2,3-트리아졸-1-일메틸)-1,3-옥사졸리딘-2-온
Pancholi et al. Asymmetric Synthesis of 2-Substituted Azetidin-3-ones via Metalated SAMP/RAMP Hydrazones
JPWO2021050824A5 (de)
CN1136810A (zh) 5-芳基异噁唑-4-基-取代的2-氨基羧酸化合物
Li et al. An approach to the anticoagulant agent rivaroxaban via an isocyanate-oxirane cycloaddition promoted by MgI2. etherate
DE602005015223D1 (de) 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-on-derivate und verwandte verbindungen zur behandlung von erkrankungen des zentralnervensystems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties